Search
News & Events
Australia’s first DNA-based COVID-19 vaccine study set to begin at The Kids Research Institute AustraliaAustralia’s first needle-free, gene-based COVID-19 vaccine study will be spear-headed in WA by The Kids Research Institute Australia thanks to almost $6 million in Coronavirus Research Response funding announced by Health Minister Greg Hunt.
News & Events
New national guideline set to tackle skin infectionsWhen health organisations in the north-west of WA requested urgent action to address the region’s high rate of skin infections, Dr Asha Bowen answered the call.
News & Events
Latest research identifies true danger of antimicrobial resistance in Australian kidsOne out of every 10 children with a bloodstream infection are infected with a multi-drug resistant organism in the nation’s first-ever surveillance study investigating the prevalence of paediatric antimicrobial resistance (AMR).
News & Events
Institute celebrates eradication of rubella in AustraliaThe eradication of rubella in Australia is evidence of the vital role vaccinations play in protecting our health, researchers at The Kids Research Institute Australia say.
News & Events
Global consortium aims to protect babies from their first week of lifeBabies are most vulnerable to life-threatening diseases in their first few weeks of life, yet current vaccines can’t be given until two months of age.
Research
Optimising detection of thrombosis in paediatric Staphylococcus aureus bacteraemia: A prospective interventional sub-study protocolStaphylococcus aureus bacteraemia (SAB) is the most common cause of sepsis, contributing to paediatric intensive care unit admission in Australia and New Zealand. While deep venous thrombosis (DVT) has been reported in children with invasive S. aureus infections, the actual frequency and possible effects of thrombosis on disease severity and outcome in paediatric SAB remain unknown. Moreover, guidance regarding imaging for paediatric SAB management are poorly defined.
Research
Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch ProtocolStaphylococcus aureus bloodstream infection is traditionally treated with at least 2 weeks of intravenous antibiotics in adults, 3-7 days in children, and often longer for those with complicated disease. The current practice of treating S. aureus bacteremia with prolonged IV antibiotics (rather than oral antibiotics) is based on historical observational research and expert opinion. Prolonged IV antibiotic therapy has significant disadvantages for patients and healthcare systems, and there is growing interest in whether a switch to oral antibiotics following an initial period of IV therapy is a safe alternative for clinically stable patients.
Research
Antifungal use in children with acute leukaemia: state of current evidence and directions for future researchInvasive fungal disease (IFD) remains a common and serious complication in children treated for leukaemia. Antifungal prescription in children with leukaemia presents unique challenges, particularly due to variation in IFD risk between and within leukaemia treatment protocols, drug toxicities and interactions between antifungals and chemotherapeutic agents.
News & Events
Major funding aims to improve skin cancer outcomes for young Aboriginal peopleVital research promoting sun smart choices and skin cancer prevention for young Aboriginal people is now underway at The Kids Research Institute Australia thanks to a $100,000 Perpetual 2024 IMPACT Philanthropy grant.
PICOBOO (The Platform Trial In COVID-19 Priming and BOOsting) Study and NOVAVAX COVID-19/Influenza Combined Vaccine Study